ClinicalTrials.gg
CompletedNCT03820414Updated Feb 11, 2021

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

A Phase 1 interventional study of CRV 101 and Placebo in Herpes Zoster and Varicella Zoster, sponsored by Curevo Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-11.

Sponsored by Curevo Inc (part of Eli Lilly and Company) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Apr 2020, 6 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Herpes Zoster with a site in United States — 5 open to participants now, 9 under way, 2 of them phase 3. Herpes Zoster · United States.

Enrollment
55th of 85
90 · median 150
Started
2019
with 2 others
Phase 1
13 of 95
none open now
Registered
74th of 95
by date
Lead sponsor
2 of 95
Curevo Inc

Among the 95 studies in Herpes Zoster with a site in United States, this one is the 55th largest by enrollment of the 85 interventional ones that give a count, is one of 3 that started in 2019, is one of 13 in phase 1, and was the 74th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

5 of the 95 studies in Herpes Zoster with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Herpes Zoster with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to evaluate the safety, tolerability, and immunogenicity of vaccine candidate CRV-101, investigational vaccine in healthy adult subjects in the United States.

03

Conditions studied

  • Herpes Zoster
  • Varicella Zoster

Browse trials for

Keywords

  • VZV, Vaccine, Shingles
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and non-pregnant females ≥ 18 to \< 50 years of age at the time of enrollment.
  2. In good general health as confirmed by a medical history and physical exam, vital signs*, and screening laboratories conducted no more than 30 days prior to study injection administration.

    *Oral Temperature \<38°C, respiratory rate \< 17 breaths pm, heart rate ≤100 bpm and >54 bpm, systolic blood pressure ≤150 mmHg and >89 mmHg, diastolic blood pressure ≤95 mmHg.

    NOTE: Athletically trained subjects with a heart rate ≥40 may be enrolled at the discretion of the principal investigator or designated licensed clinical investigator and reasoning must be documented.

  3. Screening laboratory values must be within normal range or not as determined by the PI and approved by the Medical Monitor: sodium, potassium, BUN, , AST, total , alkaline phosphatase, creatinine, random glucose, WBC with differential, , and count.
  4. Negative 1/2 antibody, surface antigen (HBsAg), and virus (HCV) antibody.
  5. Normal urinalysis or if abnormal determined to be not clinically significant by the PI and the Medical Monitor (trace protein is acceptable without medical monitor approval).
  6. Urine test result for recreational drugs/drugs of abuse that in the opinion of the PI would not be a concern for subject's safety, or ability to reliably attend visits, and perform required protocol procedures. If urine drug test is positive, reasoning for inclusion must be documented.
  7. Females of * must have a negative serum pregnancy test at screening and a negative urine pregnancy test on the day of each study vaccination (prior to vaccination), must not be breast-feeding, and women in sexual relationships with men must agree to practice acceptable ** for the 30-day period before Day 0 through 90 days after the last study injection. These precautions are necessary due to unknown effects that CRV-101 might cause in a fetus or newborn infant.

    *Not sterilized via tubal ligation, bilateral oophorectomy, hysterectomy or successful Essure® placement (permanent, non-surgical, non-hormonal sterilization) with documented radiological confirmation test at least 90 days after the procedure, and still menstruating or \< 1 year of the last menses if menopausal). defined as at least 12 months spontaneous amenorrhea and confirmed with FSH > 40 mIU/ml.

    **Includes, but is not limited to, sexual abstinence, monogamous relationship with vasectomized partner who has been vasectomized for 6 months or more prior to the subject receiving study product, barrier methods such as condoms or diaphragms with spermicide or foam, effective intrauterine devices, NuvaRing ®, and licensed hormonal methods such as implants, injectables or oral contraceptives ("the pill").

  8. Exposure to VZV as documented by one of the following: subject reported clinical history of chickenpox, previous vaccination against VZV with Varivax® (or other low-titer live-attenuated varicella vaccine), or positive serology test for VZV.
  9. Must be able to understand in English and capable of completing a study diary card in English.
  10. Must provide informed consent prior to any screening procedures performed, be able and willing to make all study visits, be reachable by telephone or personal contact by the study site personnel, and have a permanent address.
  11. Willing to abstain from donating whole blood or blood derivatives until after Day 365 visit.

Exclusion criteria

Exclusion Criteria:

  1. History of chickenpox or herpes zoster in the past 3 years.
  2. Immunization with a vaccine against herpes zoster (Zostavax® or Shingrix®).
  3. Participation in another experimental protocol with last receipt of any device, vaccine, or other immunomodulator products within the past 180 days of enrollment, or last receipt of non-device, non-vaccine, non-immunomodulator investigational products with in the last 90 days of enrollment or 5 half-lives whichever is greater, or planned participation in any other investigational study during the study period.
  4. Chronic administration (defined as more than 14 days in total) of or other immune-modifying drugs (e.g. oral or injected , such as prednisone; high dose inhaled steroids; biologics (e.g. TNF inhibitor, or other cytokine inhibitors) or cytotoxic therapies, such as chemotherapy drugs or radiation) within 180 days prior to enrollment and during the study through Day 365 visit. For corticosteroids, this will mean prednisone ≥ 0.5 mg/kg/day, or equivalent. Low dose inhaled and topical steroids are allowed.
  5. Received a blood transfusion or immunoglobulin within past 90 days of enrollment.
  6. Donated blood products (, whole blood, plasma, etc.) within past 60 days of enrollment.
  7. Received any vaccine within past 30 days prior to enrollment and no planned immunizations while on study with the exception of seasonal influenza vaccine which must not be given until 30 days after the last study injection and the Day 84 immunology blood has been drawn and a 30 day window prior to each immunology blood draw (Day 196, 365).
  8. History of disease or other causes of immunosuppressive states.
  9. History of any acute or chronic illness (including cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic or renal disorders, controlled hypertension), or use of medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine.
  10. Rash, tattoos, or any other dermatological condition that could adversely affect the vaccine injection site or interfere with its evaluation.
  11. that poses a health risk in the opinion of the Principal Investigator.
  12. Hypertension (systolic >150 or diastolic >95).
  13. History of significant psychiatric illness (including past history of suicidal ideation or attempt) with or without current use of medication.
  14. Known or suspected alcohol or drug abuse within the past 5 years.
  15. Chronic smoker (> 20 pack years).
  16. Subjects with a history of previous anaphylaxis or severe allergic reaction to vaccines or unknown allergens.
  17. Subjects who are unlikely to cooperate with the requirements of the study protocol or who are likely to be unreliable in attending study visits or other reason that the Principal Investigator determines that the subject will not be a good candidate to participate in this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    CRV101 Group 1

    Subjects receive 2 doses of the candidate CRV-101 formulation 1, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.

    Biological: CRV 101

  • Experimental
    CRV 101 Group 2

    Subjects receive 2 doses of the candidate CRV-101 formulation 2, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.

    Biological: CRV 101

  • Experimental
    CRV 101 Group 3

    Subjects receive 2 doses of the candidate CRV-101 formulation 3, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.

    Biological: CRV 101

  • Experimental
    CRV 101 Group 4

    Subjects receive 2 doses of the candidate CRV-101 formulation 4, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.

    Biological: CRV 101

  • Placebo comparator
    Control Group

    Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.

    Biological: Placebo

Interventions

  • BiologicalCRV 101

    (Different formulations)

  • BiologicalPlacebo

    2 doses administered IM in deltoid region of non-dominant arm

    Also known as: Saline injection

06

What researchers measure

Primary outcomes

  1. The number of subjects experiencing solicited local injection site reactions within 7 days following each study injection.

    Time frame: 7 Days

  2. The number of subjects experiencing solicited systemic reactions within 7 days following each study injection.

    Time frame: 7 Days

  3. The number of subjects spontaneously reporting unsolicited adverse events from Day 0 through 28 days after the last injection.

    Time frame: 28 Days

  4. The number of medically-attended adverse events considered related to any of the study injections reported at any point during the study period events and potential immune-mediated medical conditions considered related to any of the study injections

    Time frame: 421 Days

Secondary outcomes

  1. The frequencies of vaccine protein-specific T cells elicited by the CRV101 study vaccine at specified time points.

    Time frame: Day 0, 7, 28, 56, 63, 84, 196, and 365

  2. The levels of vaccine protein-specific antibodies elicited by the CRV101 study vaccine at specified time points

    Time frame: Day 0, 7, 28, 56, 63, 84, 196, and 365

07

Study locations

1 site
  • The Center for Pharmaceutical Research
    Kansas City, Missouri 64114, United States
08

References and documents

Publications

  • Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013 Jul 18;369(3):255-63. doi: 10.1056/NEJMcp1302674. PubMed 23863052 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Apr 2020, 15 months.

Of 21 phase 1 interventional studies under Herpes Zoster, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 15 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2019
First posted
Jan 29, 2019
StartActual
Jan 3, 2019
Primary completionActual
Apr 4, 2020
CompletionActual
Apr 30, 2020
Last update
Feb 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03820414
Lead sponsor
Curevo Inc
Collaborators
Access to Advanced Health Institute (AAHI), Mogam Biotechnology Research Institute, Green Cross Corporation
Responsible party
Sponsor
First posted
Jan 29, 2019
Start date
Jan 3, 2019
Primary completion
Apr 4, 2020
Completion
Apr 30, 2020
Last update
Feb 11, 2021

Study contacts

John E Ervin, MD
principal investigator · The Center for Pharmaceutical Research
Corey Casper, MD
study director · Access to Advanced Health Institute (AAHI)
Lisa Shelton
study chair · Curevo Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion